Skip to main content
Dechra Pharmaceuticals PLC logo

Dechra Pharmaceuticals PLC — Investor Relations & Filings

Ticker · DPH ISIN · US2434351043 LEI · 213800J4UVB5OWG8VX82 IL Manufacturing
Open in API
Filings indexed 1,018 across all filing types
Latest filing 2023-08-03 M&A Activity
Country GB United Kingdom
Listing IL DPH

About Dechra Pharmaceuticals PLC

https://www.dechra.com/

Dechra Pharmaceuticals PLC is a global specialist business focused on veterinary pharmaceuticals and related products. The company's expertise encompasses the development, manufacture, marketing, and sale of high-quality veterinary medicines. Its product portfolio includes both novel and differentiated generic pharmaceuticals, with a significant focus on products for companion animals. Dechra provides solutions and support to veterinary professionals worldwide to improve animal health and welfare.

Recent filings

Filing Released Lang Actions
Form 8.3 - Dechra Pharmaceuticals PLC
M&A Activity Classification · 98% confidence The document is explicitly titled "Form 8.3 - Dechra Pharmaceuticals PLC" and references "Rule 8.3 of the Takeover Code (the “Code”)". This form is a mandatory disclosure required when a person or entity acquires or deals in shares during a takeover offer, disclosing their interests and dealings. This type of filing relates directly to corporate control transactions and insider/major shareholder activity during a bid, which falls under the scope of takeover/M&A activity reporting. While it involves share dealings, the context is specifically a takeover disclosure (Rule 8.3), making it most closely aligned with M&A Activity (TAR) rather than general insider trading (DIRS) or general share transactions (POS).
2023-08-03 English
Holding(s) in Company
Major Shareholding Notification Classification · 98% confidence The document is titled 'TR-1: Standard form for notification of major holdings' and is issued via 'RNS Number : 2075I' on '03 August 2023'. This form is used to report changes in significant share ownership (crossing thresholds) by individuals or entities, which directly corresponds to the definition of Major Shareholding Notification (MRQ). Although it is distributed via RNS, the specific content is a mandatory regulatory disclosure about share ownership changes, making MRQ the most precise classification over the general RNS fallback.
2023-08-03 English
Form 8.3 - Dechra Pharmaceuticals plc
Major Shareholding Notification Classification · 99% confidence The document is explicitly titled "FORM 8.3 - PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE" and references "Rule 8.3 of the Takeover Code (the 'Code')". This form is used to disclose interests and dealings in the securities of an offeror or offeree during a takeover bid, which falls under insider trading/director dealing disclosures related to corporate actions, but specifically mandated by the Takeover Code. Among the provided categories, 'Director's Dealing' (DIRS) is the closest fit for reporting personal share transactions by insiders/significant holders, even though this specific form (Form 8.3) is unique to takeover situations. It is a disclosure of dealings/positions by a significant holder (Millennium International Management LP) in relation to an offer concerning Dechra Pharmaceuticals plc. Since there is no specific code for 'Takeover Disclosure Form 8.3', DIRS (Director's Dealing) is the most appropriate classification for insider/significant shareholder transaction reporting.
2023-08-02 English
Form 8.3 - Dechra Pharmaceuticals PLC
Major Shareholding Notification Classification · 95% confidence The document is explicitly titled 'FORM 8.3' and references 'Rule 8.3 of the Takeover Code'. This form is used for 'PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE' concerning an offer (in this case, related to Dechra Pharmaceuticals PLC). This type of disclosure relates to insider dealings or significant ownership changes during a takeover or merger scenario. Among the provided codes, 'Director's Dealing (DIRS)' covers personal share transactions by executives, and 'M&A Activity (TAR)' covers takeover bids. Since this is a mandatory disclosure related to a potential or ongoing takeover/offer situation (as indicated by the reference to the Takeover Code and the structure of Form 8.3), it is most closely aligned with the context of M&A activity, although it specifically details insider/significant shareholder dealing during that period. However, Form 8.3 is a specific disclosure required under the Takeover Code, which governs M&A. Given the options, 'Director's Dealing (DIRS)' is often used for insider trades, but Form 8.3 is broader, covering any person with a 1% interest during an offer period. Since the document details dealings and positions related to an offer, and there isn't a specific code for 'Takeover Disclosure Form 8.3', we must choose the closest fit. Director's Dealing (DIRS) is for personal transactions by directors. This is a disclosure by a fund manager (Farallon Capital Europe LLP) regarding their position during an offer period for Dechra Pharmaceuticals PLC. This strongly suggests involvement in a takeover/merger scenario. Therefore, TAR (M&A Activity) is the most appropriate category capturing the context of the filing, even though it details specific dealings.
2023-08-02 English
Form 8.3 - Dechra Pharmaceuticals plc
Major Shareholding Notification Classification · 99% confidence The document is explicitly titled 'FORM 8.3 - Dechra Pharmaceuticals plc' and references 'Rule 8.3 of the Takeover Code (the “Code”)'. This form is a 'PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE'. This type of disclosure relates to transactions or holdings by parties involved in a takeover bid, which falls under the scope of M&A activity or related regulatory disclosures concerning takeovers. Since the definitions provided do not have a specific code for 'Takeover Code Disclosure Form 8.3', the closest relevant category is 'M&A Activity' (TAR), as this form is directly triggered by a takeover situation involving Dechra Pharmaceuticals plc. Alternatively, it could be a general 'Regulatory Filing' (RNS), but TAR is more specific to the context of the content (Takeover Code). Given the nature of the disclosure (dealing disclosure related to an offer), TAR is the most appropriate fit among the provided options.
2023-08-01 English
Holding(s) in Company
Major Shareholding Notification Classification · 99% confidence The document is explicitly labeled with "RNS Number : 8928H" and contains the standard header/footer information associated with RNS (Regulatory News Service) announcements from the London Stock Exchange. The content details a "TR-1: Standard form for notification of major holdings" filed by JPMorgan Chase & Co. regarding an acquisition/disposal of voting rights in Dechra Pharmaceuticals PLC. This type of mandatory disclosure regarding changes in significant share ownership thresholds directly corresponds to the Major Shareholding Notification category.
2023-08-01 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.